Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 97.51% is in line with its 5-year average of 100.00%, near the high end of its 5-year range (60.60%–100.00%).
0.15% above its 12-month average of 97.37%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.81%.
GROSS MARGIN
97.51%
GROSS MARGIN AVG TTM
97.37%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
100.00%
GROSS MARGIN AVG 10Y
97.43%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.15%
CURRENT VS 3Y AVG
-2.49%
CURRENT VS 5Y AVG
-2.49%
CURRENT VS 10Y AVG
+0.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.92%
median of 850 covered companies
CURRENT VS SECTOR MEDIAN
+138.27%
vs the sector median at left
Yarrow Bioscience Inc
Market Cap
$179.39M
Gross Margin
97.51%
TTM Avg
97.37%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$175.93M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$181.30M
Gross Margin
0.65%
TTM Avg
0.33%
3Y Avg
50.16%
5Y Avg
60.13%
Market Cap
$182.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$173.76M
Gross Margin
83.01%
TTM Avg
91.50%
3Y Avg
95.75%
5Y Avg
97.17%
Market Cap
$183.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$173.52M
Gross Margin
62.24%
TTM Avg
61.05%
3Y Avg
61.66%
5Y Avg
60.51%
Market Cap
$172.20M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$172.02M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $179.39M | 97.51% | 97.37% | 100.00% | 100.00% |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.93M | 0.00% | 50.00% | 25.00% | 16.67% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.30M | 0.65% | 0.33% | 50.16% | 60.13% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | 83.01% | 91.50% | 95.75% | 97.17% |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| Journey Medical Corporation (DERM)vs › | $173.52M | 62.24% | 61.05% | 61.66% | 60.51% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.20M | 100.00% | 100.00% | 100.00% | 100.00% |
| Cue Biopharma, Inc. (CUE)vs › | $172.02M | 99.69% | 100.00% | -73.48% | -190.92% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | 67.59% | 75.78% | 75.92% | 75.58% |
Gross Margin
97.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.81% |
| 2026-03-31 | 93.02% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 60.60% |
| 2021-09-30 | 78.95% |
| 2021-06-30 | 90.51% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 87.54% |
| 2020-09-30 | 88.65% |
| 2020-06-30 | 98.15% |
| 2020-03-31 | 84.51% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 0.00% |
